Johnson & Johnson has signed up as the first sponsor of YouTube's lineup of free original programming for the fall, as exclusive sponsor of a show…
With an expert panel review set for Thursday, FDA staff found Pfizer's biosimilar candidate nearly identical to Amgen's blockbuster anemia med Epogen.
Pfizer has launched its first TV ad for breast cancer drug Ibrance, coming hot on the heels of the FDA approval of Novartis' first-ever in-class…
Talk about going on a roll. Merck’s Keytruda nabbed a first-ever FDA approval to treat a very specific type of tumor anywhere in the body.
A shareholder is taking it to the company’s current and former execs for “gross mismanagement” and other allegations.
It’s good to be Merck these days. Less than a week after Keytruda nabbed an FDA go-ahead in bladder cancer, it scored a speedy review in stomach cancer.
The U.K.’s competition authority claims Merck's Remicade discounts, aimed at defending against biosimilar competition, “broke competition law."
GSK's Cervarix may have been the first HPV shot approved in mainland China, but Merck's Gardasil now has an opening to gain the lead.
Alexion’s C-suite makeover continues as four top execs prepare to depart, and new CEO Ludwig Hantson makes his first key hire.
AstraZeneca finally has cardiovascular outcomes data for one of its top diabetes contenders. But the new results don’t measure up to rivals' studies.